Israel-based Insightec has secured CE mark approval for Exablate prostate system to treat locally-confined prostate cancer with MR-guided focused ultrasound (MRgFUS).
Based on the firm’s proprietary MRI-guided focused ultrasound technology, the Exablate system includes an endorectal incorporated into a treatment bed that is compatible with GE MRI 1.5 and 3T.
The system uses focused ultrasound waves to precisely target and ablate the targeted tissue in the prostate, while minimizing damage to adjacent structures.
A high-frequency 1,000-element phased array transducer includes ultrasound energy that helps to deliver focal therapy under MRI guidance and real time thermal feedback. It allows the physician to control and personalize the therapy.
The treatment is carried out under MRI guidance for high resolution visualization of the patient’s anatomy, as well as real-time temperature monitoring.
According to the company, one in six men will be diagnosed with prostate cancer during their lifetime and many patients are diagnosed with locally-confined disease with low or intermediate risk for progression.
Memorial Sloan Kettering Cancer Center MPH surgeon Behfar Ehdaie said: “Focused ultrasound treatment for prostate cancer may offer a novel method to re-think the management of locally-confined prostate cancer in select patients.”
Insightec CEO and chairman Dr Maurice Ferré said: “Insightec has reached another important strategic milestone. We remain focused on expanding the Exablate technology platform to address multiple clinical indications and treat more patients worldwide.”